Article

Axial Spondyloarthritis Treatment Recommendations

In this slideshow, we highlight the 13 ASAS-EULAR treatment management guidelines for axial spondyloarthritis.

The European League Against Rheumatism (EULAR) and the Assessment of SpondyloArthritis International Society (ASAS) have updated its 2010 treatment management guidelines for axial spondyloarthritis. In this slideshow, we highlight the 13 recommendations.Related content from Rheumatology Network.Here’s What You Should Know About Axial SpondyloarthritisAxial Spondyloarthritis Guidelines Updated and Simplified 

References:

Desiree van der Jeijde, Sofia Ramiro, Robert Landewe, et al. “2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis” Annals of the Rheumatic Diseases. 2017;0:1–14. DOI:10.1136/annrheumdis-2016-210770 

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Related Content
Gerd R. Burmester, MD, Professor of Medicine, Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, and Humboldt University and Free University
February 4th 2025

Tocilizumab Biosimilar Approved for Rheumatological Diseases, COVID-19

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Ryan Stultz, MD, PhD, Clinician Researcher, Division of Rheumatology, University of Washington, Seattle
January 29th 2025

NLR and MLR May Predict Gout Flare and CVD Mortality Risk

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Orrin M. Troum, MD, Division of Rheumatology, University of Southern California Keck School of Medicine and Providence Saint John’s Health Center
January 26th 2025

Pegloticase + MTX for Gout Not Effective After Pegloticase Monotherapy

Victoria Johnson
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
January 25th 2025

Psoriatic Arthritis Care Priorities Differ Between Patient and Clinicians

Victoria Johnson
© 2025 MJH Life Sciences

All rights reserved.